Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Paul Weaver/SOPA Images/LightRocket via Getty Images

Merck said Friday that an experimental pill it is developing with Ridgeback Biotherapeutics reduced the risk of hospitalization or death from COVID-19 by around 50% in a clinical trial.

Why it matters: An oral antiviral drug designed to prevent or treat COVID-19 could be a key tool to combat the pandemic, since not all people will get vaccinated and because it will take potentially years to vaccinate people in certain countries around the world.

  • Merck said it will apply for an emergency use authorization from the Food and Drug Administration "as soon as possible" to begin distributing molnupiravir because of the results.
  • It will also submit applications to international regulatory agencies.

What they're saying: “More tools and treatments are urgently needed to fight the COVID-19 pandemic, which has become a leading cause of death and continues to profoundly affect patients, families, and societies and strain health care systems all around the world," Robert Davis, Merck CEO and president, said.

  • "With these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic and will add to Merck’s unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most."

By the numbers: The results are from a trial that initially had a sample size of 775 patients but was soon expanded to 1,550 patients because of compelling efficacy results, Merck said.

  • All patients had a laboratory-confirmed mild-to-moderate case of COVID-19 and at least one risk factor associated with poor disease outcome at the start of the study.
  • 7.3% of patients taking molnupiravir during the trial were either hospitalized or died at the end of 30 days, compared to 14.1% of those receiving a placebo.
  • In June, the Biden administration agreed to buy about $1.2 billion worth of molnupiravir. The company said it expects to produce 10 million total doses of the drug by the end of 2021.

The big picture: Merck's molnupiravir is one of several antiviral medications currently under development or testing.

Go deeper: The antivirals are (hopefully) coming

Go deeper

21 hours ago - Health

J&J expects $2.5 billion of vaccine sales this year

J&J's COVID-19 vaccine. Photo: Paul Hennessy/SOPA Images/LightRocket via Getty Images

Johnson & Johnson registered $502 million of global revenue from its COVID-19 vaccine in the third quarter, bringing year-to-date vaccine sales to $766 million.

The big picture: J&J, which is selling the vaccine at a not-for-profit price of $7.50 per dose, still expects to generate $2.5 billion of COVID vaccine sales this year, executives said Tuesday. But that total will still dwarf the use and sales of the vaccines made by Pfizer/BioNTech and Moderna.

19 hours ago - Health

Virginia governor has had long COVID for more than a year

Gov. Ralph Northam. Photo by Zach Gibson/Getty Images

Virginia Gov. Ralph Northam still has long COVID-19 symptoms more than a year after his initial infection, he said in an interview with the Virginian-Pilot.

Why it matters: The Democratic governor is one of millions of Americans suffering from symptoms of long COVID, which could have serious implications for employers and social programs if enough people can no longer work because of it, per Axios' Caitlin Owens.

GE to mandate COVID vaccinations for U.S. workers

Photo: Sebastien Bozon/AFP via Getty Images

General Electric will require all of its workers in the U.S. to be vaccinated against COVID-19, citing President Biden's executive order for federal contractors, the company confirmed to Axios on Tuesday.

Why it matters: General Electric is the latest in a slew of major companies to mandate the vaccine for workers, following in the footsteps of American Airlines, Tyson Foods and Microsoft, among others.